Pharming Group N.V. (AMS:PHARM)

Pharming Group Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	158.28	145.31	54.94	61.74	207.34	191.92
Short-Term Investments	-	33.8	112.95	151.68	-	-
Cash & Short-Term Investments	158.28	179.1	167.89	213.42	207.34	191.92
Cash Growth	25.61%	6.68%	-21.33%	2.93%	8.03%	-6.45%
Accounts Receivable	56.98	41.77	41.53	35.41	20.96	18.08
Other Receivables	-	6.67	8.64	7.21	4.37	9.52
Receivables	56.98	48.44	50.17	42.62	25.33	27.59
Inventory	65.43	64.9	55.72	56.76	42.33	27.31
Prepaid Expenses	-	6.26	4.65	3.54	2.29	2.39
Restricted Cash	-	0.76	-	-	0.21	0.23
Other Current Assets	-	0	-	-	-	-
Total Current Assets	280.69	299.47	278.44	316.34	277.5	249.44
Property, Plant & Equipment	20.48	23.97	24.13	33.47	39.15	33.17
Long-Term Investments	8.58	8.65	4.23	10.4	9.73	8.65
Goodwill	-	3.32	-	-	-	-
Other Intangible Assets	128.08	132.22	61.04	71.27	74.87	83.57
Long-Term Deferred Tax Assets	28.84	31.02	30.54	29.76	22.97	21.22
Long-Term Deferred Charges	-	-	-	-	0.25	0.27
Other Long-Term Assets	1.32	1.32	1.6	1.62	1.33	1.01
Total Assets	467.98	499.96	399.99	462.85	425.8	397.32

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	82.32	8.55	10.1	16.02	8.75	7.6
Accrued Expenses	-	91.31	53.22	50.27	43.61	33.34
Current Portion of Long-Term Debt	5.47	5.34	4.25	1.82	1.77	1.88
Current Portion of Leases	3.58	3.37	2.95	3.62	3.47	2.42
Current Income Taxes Payable	-	6.04	3.28	6.23	2.1	1.51
Other Current Liabilities	1.88	1.19	-	-	-	0.03
Total Current Liabilities	93.25	115.79	73.8	77.97	59.7	46.77
Long-Term Debt	92.4	92.72	78.15	136.6	131.62	139.01
Long-Term Leases	11.85	14.35	26.97	29.51	29.84	18.46
Other Long-Term Liabilities	-	-	-	-	-	0.17
Total Liabilities	197.49	222.86	178.92	244.07	221.16	204.4

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	8.08	8.01	7.77	7.67	7.51	7.43
Additional Paid-In Capital	520.31	513.26	488.99	478.43	462.3	455.25
Retained Earnings	-271.36	-258	-287.92	-265.5	-265.17	-269.77
Comprehensive Income & Other	13.46	13.84	12.23	-1.82	-	-
Shareholders' Equity	270.49	277.1	221.06	218.78	204.64	192.92
Total Liabilities & Equity	467.98	499.96	399.99	462.85	425.8	397.32

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	113.3	115.78	112.31	171.55	166.69	161.76
Net Cash (Debt)	44.99	63.33	55.58	41.88	40.65	30.16
Net Cash Growth	-	13.94%	32.72%	3.03%	34.76%	-30.18%
Net Cash Per Share	0.06	0.08	0.08	0.06	0.06	0.04
Filing Date Shares Outstanding	707.78	701.68	683.93	673.44	656.35	648.75
Total Common Shares Outstanding	707.78	701.68	680.31	671.07	656.35	648.75
Working Capital	187.44	183.68	204.64	238.37	217.8	202.67
Book Value Per Share	0.38	0.39	0.32	0.33	0.31	0.30
Tangible Book Value	142.41	141.56	160.02	147.51	129.77	109.35
Tangible Book Value Per Share	0.20	0.20	0.24	0.22	0.20	0.17
Land	-	-	-	-	-	0.03
Machinery	-	10.57	9.3	9.66	8.28	14.84
Construction In Progress	-	-	0.15	0.18	0.01	0.62
Leasehold Improvements	-	6.4	5.43	5.55	5.28	5.71

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 16, 2026

Data Sources Report a data error